1. Home
  2. EXFY vs KPTI Comparison

EXFY vs KPTI Comparison

Compare EXFY & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$0.94

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$9.36

Market Cap

148.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
KPTI
Founded
2008
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
148.0M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
EXFY
KPTI
Price
$0.94
$9.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$4.50
$22.17
AVG Volume (30 Days)
557.3K
676.3K
Earning Date
06-01-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$142,101,000.00
$146,067,000.00
Revenue This Year
$4.44
$0.84
Revenue Next Year
$0.56
$46.25
P/E Ratio
N/A
N/A
Revenue Growth
2.06
0.57
52 Week Low
$1.17
$3.51
52 Week High
$3.87
$10.99

Technical Indicators

Market Signals
Indicator
EXFY
KPTI
Relative Strength Index (RSI) 25.73 61.64
Support Level N/A $5.60
Resistance Level $1.54 N/A
Average True Range (ATR) 0.10 1.03
MACD -0.02 0.13
Stochastic Oscillator 10.23 67.68

Price Performance

Historical Comparison
EXFY
KPTI

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: